Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

NCT00441987 ↗

Phase 1 Completed 96 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.

Timeline

Start: 2007-02
Primary completion: 2009-07
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Begacestat	Small molecule	—	Oral

Indications

No indication recorded.